JP2019536460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536460A5 JP2019536460A5 JP2019529636A JP2019529636A JP2019536460A5 JP 2019536460 A5 JP2019536460 A5 JP 2019536460A5 JP 2019529636 A JP2019529636 A JP 2019529636A JP 2019529636 A JP2019529636 A JP 2019529636A JP 2019536460 A5 JP2019536460 A5 JP 2019536460A5
- Authority
- JP
- Japan
- Prior art keywords
- immune checkpoint
- cells
- genetically engineered
- pharmaceutical composition
- engineered cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004027 cell Anatomy 0.000 claims description 146
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 68
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 65
- 229940126546 immune checkpoint molecule Drugs 0.000 claims description 33
- 230000037361 pathway Effects 0.000 claims description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 28
- 102000005962 receptors Human genes 0.000 claims description 28
- 108020003175 receptors Proteins 0.000 claims description 28
- 210000004369 blood Anatomy 0.000 claims description 26
- 239000008280 blood Substances 0.000 claims description 26
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 25
- 108091007433 antigens Proteins 0.000 claims description 25
- 102000036639 antigens Human genes 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 230000003902 lesion Effects 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 210000001519 tissue Anatomy 0.000 claims description 11
- -1 CD44v7 / 8 Proteins 0.000 claims description 10
- 210000001124 body fluid Anatomy 0.000 claims description 10
- 239000010839 body fluid Substances 0.000 claims description 10
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000001605 fetal effect Effects 0.000 claims description 8
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 229960002621 pembrolizumab Drugs 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 4
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 4
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 108091008874 T cell receptors Proteins 0.000 claims description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 4
- 208000008383 Wilms tumor Diseases 0.000 claims description 4
- 208000026448 Wilms tumor 1 Diseases 0.000 claims description 4
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 4
- 101710127857 Wilms tumor protein Proteins 0.000 claims description 4
- 229960005305 adenosine Drugs 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 102000036215 folic acid binding proteins Human genes 0.000 claims description 4
- 108091011001 folic acid binding proteins Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000004068 intracellular signaling Effects 0.000 claims description 4
- 229960005386 ipilimumab Drugs 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 3
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 3
- 229960003852 atezolizumab Drugs 0.000 claims description 3
- 229950009791 durvalumab Drugs 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 2
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 102000009346 Adenosine receptors Human genes 0.000 claims description 2
- 108050000203 Adenosine receptors Proteins 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 108010072524 BKT140 Proteins 0.000 claims description 2
- 102100024263 CD160 antigen Human genes 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims description 2
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 2
- 102000016736 Cyclin Human genes 0.000 claims description 2
- 108050006400 Cyclin Proteins 0.000 claims description 2
- 108010060273 Cyclin A2 Proteins 0.000 claims description 2
- 102100025191 Cyclin-A2 Human genes 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 101150029707 ERBB2 gene Proteins 0.000 claims description 2
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102100038595 Estrogen receptor Human genes 0.000 claims description 2
- 101150032879 Fcrl5 gene Proteins 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 2
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims description 2
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- 108010073816 IgE Receptors Proteins 0.000 claims description 2
- 102000009438 IgE Receptors Human genes 0.000 claims description 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 2
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 claims description 2
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 2
- 102100023123 Mucin-16 Human genes 0.000 claims description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 claims description 2
- 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 claims description 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 2
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 102100025803 Progesterone receptor Human genes 0.000 claims description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
- 108091008605 VEGF receptors Proteins 0.000 claims description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 2
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 2
- 229950002916 avelumab Drugs 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 229960004669 basiliximab Drugs 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 108010038795 estrogen receptors Proteins 0.000 claims description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 102000006815 folate receptor Human genes 0.000 claims description 2
- 108020005243 folate receptor Proteins 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 229950004563 lucatumumab Drugs 0.000 claims description 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 2
- JJVZSYKFCOBILL-MKMRYRNGSA-N motixafortide Chemical compound NCCCC[C@@H]1NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCCN)NC1=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)c1ccc(F)cc1 JJVZSYKFCOBILL-MKMRYRNGSA-N 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 230000002688 persistence Effects 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 108090000468 progesterone receptors Proteins 0.000 claims description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 2
- 101150047061 tag-72 gene Proteins 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 229940124644 immune regulator Drugs 0.000 claims 16
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940125565 BMS-986016 Drugs 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229940056913 eftilagimod alfa Drugs 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 229940121569 ieramilimab Drugs 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229950005972 urelumab Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 34
- 239000002955 immunomodulating agent Substances 0.000 description 11
- 229940121354 immunomodulator Drugs 0.000 description 11
- 230000002584 immunomodulator Effects 0.000 description 6
- 229960004942 lenalidomide Drugs 0.000 description 4
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical group C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 3
- 238000011285 therapeutic regimen Methods 0.000 description 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960002806 daclizumab Drugs 0.000 description 2
- 229960000688 pomalidomide Drugs 0.000 description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 description 1
- 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011273 incision biopsy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 229950007213 spartalizumab Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023046854A JP2023078394A (ja) | 2016-12-03 | 2023-03-23 | Ｃａｒ－ｔ細胞の調節方法 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662429740P | 2016-12-03 | 2016-12-03 | |
| US62/429,740 | 2016-12-03 | ||
| US201762444784P | 2017-01-10 | 2017-01-10 | |
| US62/444,784 | 2017-01-10 | ||
| US201762492950P | 2017-05-01 | 2017-05-01 | |
| US62/492,950 | 2017-05-01 | ||
| US201762514777P | 2017-06-02 | 2017-06-02 | |
| US62/514,777 | 2017-06-02 | ||
| US201762515512P | 2017-06-05 | 2017-06-05 | |
| US62/515,512 | 2017-06-05 | ||
| US201762549391P | 2017-08-23 | 2017-08-23 | |
| US62/549,391 | 2017-08-23 | ||
| US201762580414P | 2017-11-01 | 2017-11-01 | |
| US62/580,414 | 2017-11-01 | ||
| PCT/US2017/064363 WO2018102786A1 (en) | 2016-12-03 | 2017-12-01 | Methods for modulation of car-t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023046854A Division JP2023078394A (ja) | 2016-12-03 | 2023-03-23 | Ｃａｒ－ｔ細胞の調節方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019536460A JP2019536460A (ja) | 2019-12-19 |
| JP2019536460A5 true JP2019536460A5 (enExample) | 2021-01-21 |
Family
ID=60923893
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529636A Withdrawn JP2019536460A (ja) | 2016-12-03 | 2017-12-01 | Ｃａｒ−ｔ細胞の調節方法 |
| JP2023046854A Withdrawn JP2023078394A (ja) | 2016-12-03 | 2023-03-23 | Ｃａｒ－ｔ細胞の調節方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023046854A Withdrawn JP2023078394A (ja) | 2016-12-03 | 2023-03-23 | Ｃａｒ－ｔ細胞の調節方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190358262A1 (enExample) |
| EP (1) | EP3548083A1 (enExample) |
| JP (2) | JP2019536460A (enExample) |
| KR (2) | KR20190104529A (enExample) |
| CN (1) | CN110248678A (enExample) |
| AU (1) | AU2017368332A1 (enExample) |
| BR (1) | BR112019011025A2 (enExample) |
| CA (1) | CA3045508A1 (enExample) |
| MA (1) | MA46961A (enExample) |
| MX (1) | MX2019006285A (enExample) |
| WO (1) | WO2018102786A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190084053A (ko) | 2016-10-13 | 2019-07-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | 트립토판 대사 경로 조절인자 관련 면역 치료 방법 및 조성물 |
| CA3061945A1 (en) * | 2017-05-01 | 2018-11-08 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
| WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| BR112020008638A2 (pt) | 2017-11-01 | 2020-10-20 | Juno Therapeutics Inc | receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma) |
| EP3801572B1 (en) * | 2018-06-01 | 2024-07-03 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
| US20210221889A1 (en) * | 2018-06-08 | 2021-07-22 | Atomic Energy Of Canada Limited/Ènergie Atomique Du Canada Limitèe | Use of a checkpoint inhibitor in combination with ultralow dose whole body irradiation |
| MX2021005366A (es) | 2018-11-08 | 2021-09-10 | Juno Therapeutics Inc | Metodos y combinaciones para el tratamiento y modulacion de celulas t. |
| WO2020123388A1 (en) * | 2018-12-11 | 2020-06-18 | Board Of Regents, The University Of Texas System | Radiotherapies and uses thereof |
| EP3962498A4 (en) * | 2019-04-30 | 2023-05-31 | Memorial Sloan Kettering Cancer Center | Combination therapies |
| GB201906202D0 (en) * | 2019-05-02 | 2019-06-19 | Autolus Ltd | Cell |
| EP4055383A1 (en) | 2019-11-05 | 2022-09-14 | Juno Therapeutics, Inc. | Methods of determining attributes of therapeutic t cell compositions |
| IL292665B1 (en) * | 2019-11-06 | 2025-10-01 | Kite Pharma Inc | Chimeric antigen receptor T cell therapy |
| MX2022008648A (es) | 2020-01-23 | 2022-12-15 | The Children´S Medical Center Corp | Diferenciacion de celulas t sin estroma a partir de celulas madre pluripotentes humanas. |
| JP7727662B2 (ja) | 2020-05-13 | 2025-08-21 | ジュノー セラピューティクス インコーポレイテッド | 臨床応答に関連する特徴量の特定方法およびその使用 |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
Family Cites Families (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5565566A (en) | 1987-04-24 | 1996-10-15 | Discovery Therapeutics, Inc. | N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists |
| US5298508A (en) | 1988-07-19 | 1994-03-29 | The United States Of America As Represented By The Department Of Health And Human Services | Irreversible inhibitors of adenosine receptors |
| US5147355A (en) | 1988-09-23 | 1992-09-15 | Brigham And Womens Hospital | Cryoablation catheter and method of performing cryoablation |
| ATE114507T1 (de) | 1988-12-28 | 1994-12-15 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
| US5452720A (en) | 1990-09-05 | 1995-09-26 | Photoelectron Corporation | Method for treating brain tumors |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| US5429582A (en) | 1991-06-14 | 1995-07-04 | Williams; Jeffery A. | Tumor treatment |
| US5424297A (en) | 1992-04-27 | 1995-06-13 | University Of Virginia Alumni Patents Foundation | Adenosine dextran conjugates |
| US5596619A (en) | 1992-08-21 | 1997-01-21 | Nomos Corporation | Method and apparatus for conformal radiation therapy |
| US5523058A (en) | 1992-09-16 | 1996-06-04 | Hitachi, Ltd. | Ultrasonic irradiation apparatus and processing apparatus based thereon |
| US5620479A (en) | 1992-11-13 | 1997-04-15 | The Regents Of The University Of California | Method and apparatus for thermal therapy of tumors |
| US5437673A (en) | 1993-02-04 | 1995-08-01 | Cryomedical Sciences, Inc. | Closed circulation tissue warming apparatus and method of using the same in prostate surgery |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| AU6781194A (en) | 1993-05-03 | 1994-11-21 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists |
| IL108918A (en) | 1994-03-10 | 1997-04-15 | Medic Lightech Ltd | Apparatus for efficient photodynamic treatment |
| US5504090A (en) | 1994-03-30 | 1996-04-02 | Trustees Of The University Of Pennsylvania | Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5670501A (en) | 1994-09-01 | 1997-09-23 | Discovery Therapeutics, Inc. | N-substituted 9-alkyladenines |
| US5549639A (en) | 1994-09-16 | 1996-08-27 | Sandia Corporation | Non-invasive hyperthermia apparatus including coaxial applicator having a non-invasive radiometric receiving antenna incorporated therein and method of use thereof |
| WO1996013593A2 (en) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Soluble single chain t cell receptors |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
| US5658234A (en) | 1995-07-24 | 1997-08-19 | J. D. Technologies, Inc. | Method for treating tumors |
| US5776175A (en) | 1995-09-29 | 1998-07-07 | Esc Medical Systems Ltd. | Method and apparatus for treatment of cancer using pulsed electromagnetic radiation |
| ATE548351T1 (de) | 1996-01-29 | 2012-03-15 | Us Of America Represented By The Secretary Dept Of Health And Human Services | Dihydropyridin-pyridin-, benzopyranon- und triazolochinazolin-derivate, deren herstellung und verwendung als adenosinrezeptor-antagonisten |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| US5654279A (en) | 1996-03-29 | 1997-08-05 | The Regents Of The University Of California | Tissue destruction in cryosurgery by use of thermal hysteresis |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| PL195916B1 (pl) | 1996-07-24 | 2007-11-30 | Celgene Corp | Izomery optyczne podstawionej 1-okso-izoindoliny i 1,3-diokso-izoindoliny, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| US6038283A (en) | 1996-10-24 | 2000-03-14 | Nomos Corporation | Planning method and apparatus for radiation dosimetry |
| US5786360A (en) | 1996-11-19 | 1998-07-28 | Link Technology Incorporated | A1 adenosine receptor antagonists |
| JP3784419B2 (ja) | 1996-11-26 | 2006-06-14 | 三菱電機株式会社 | エネルギー分布を形成する方法 |
| US6099554A (en) | 1997-04-02 | 2000-08-08 | Wound Healing Of Oklahoma | Laser light delivery method |
| US6027499A (en) | 1997-05-23 | 2000-02-22 | Fiber-Tech Medical, Inc. (Assignee Of Jennifer B. Cartledge) | Method and apparatus for cryogenic spray ablation of gastrointestinal mucosa |
| US6165440A (en) | 1997-07-09 | 2000-12-26 | Board Of Regents, The University Of Texas System | Radiation and nanoparticles for enhancement of drug delivery in solid tumors |
| US6009351A (en) | 1997-07-14 | 1999-12-28 | Urologix, Inc. | System and method for transurethral heating with rectal cooling |
| ATE533784T1 (de) | 1997-10-02 | 2011-12-15 | Altor Bioscience Corp | Lösliche, einzelkettige proteine des t- zellrezeptors |
| US6015541A (en) | 1997-11-03 | 2000-01-18 | Micro Therapeutics, Inc. | Radioactive embolizing compositions |
| US5885276A (en) | 1997-12-02 | 1999-03-23 | Galil Medical Ltd. | Method and device for transmyocardial cryo revascularization |
| JP3053389B1 (ja) | 1998-12-03 | 2000-06-19 | 三菱電機株式会社 | 動体追跡照射装置 |
| TW496741B (en) | 1998-03-12 | 2002-08-01 | Dept Of Health R O C | Radioactive particles and method for producing the same |
| JP4695259B2 (ja) | 1998-03-16 | 2011-06-08 | セルジーン コーポレイション | ２−（２，６−ジオキソピペリジン−３−イル）イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用 |
| WO1999052552A1 (en) | 1998-04-15 | 1999-10-21 | Brigham & Women's Hospital, Inc. | T cell inhibitory receptor compositions and uses thereof |
| US6001054A (en) | 1998-05-19 | 1999-12-14 | Regulla; D. F. | Method and apparatus for differential energy application for local dose enhancement of ionizing radiation |
| DK1066380T3 (da) | 1998-05-19 | 2002-01-28 | Avidex Ltd | Opløselig T-cellereceptor |
| US6393096B1 (en) | 1998-05-27 | 2002-05-21 | Nomos Corporation | Planning method and apparatus for radiation dosimetry |
| EP0960601B1 (en) | 1998-05-28 | 2006-10-11 | Terumo Kabushiki Kaisha | Tissue irradiation apparatus |
| US6326390B1 (en) | 1998-08-25 | 2001-12-04 | King Pharmaceuticals Reseach And Development, Inc. | Use of adenosine A3 receptor antagonists to inhibit tumor growth |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| US6163726A (en) | 1998-09-21 | 2000-12-19 | The General Hospital Corporation | Selective ablation of glandular tissue |
| US6335961B1 (en) | 1998-10-06 | 2002-01-01 | Siemens Medical Systems, Inc. | Integrated high definition intensity multileaf collimator system which provides improved conformal radiation therapy while minimizing leakage |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| WO2000040299A1 (en) | 1999-01-06 | 2000-07-13 | Ball Semiconductor, Inc. | Radiation dosimetry system |
| US6383180B1 (en) | 1999-01-25 | 2002-05-07 | Cryocath Technologies Inc. | Closed loop catheter coolant system |
| US6179766B1 (en) | 1999-01-28 | 2001-01-30 | Gregg A. Dickerson | Methods of breast cancer treatment |
| US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| US6313131B1 (en) | 1999-02-16 | 2001-11-06 | Upsher-Smith Laboratories, Inc. | Method of kidney treatment |
| AU771015B2 (en) | 1999-03-18 | 2004-03-11 | Celgene Corporation | Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels |
| US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
| US6245005B1 (en) | 1999-07-16 | 2001-06-12 | International Business Machines Corporation | Method and apparatus for facilitating radiation treatment of deep tumors |
| US6319189B1 (en) | 1999-09-13 | 2001-11-20 | Isotron, Inc. | Methods for treating solid tumors using neutron therapy |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| US6470217B1 (en) | 2000-04-13 | 2002-10-22 | Celsion Corporation | Method for heating ductal and glandular carcinomas and other breast lesions to perform thermal downsizing and a thermal lumpectomy |
| US6449336B2 (en) | 2000-05-19 | 2002-09-10 | Siyong Kim | Multi-source intensity-modulated radiation beam delivery system and method |
| WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
| US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| GB0100624D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| ES2338534T3 (es) | 2001-02-27 | 2010-05-10 | The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services | Analogos de talidomina como inhibidores de la angiogenesis. |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| JP4317940B2 (ja) | 2001-08-31 | 2009-08-19 | イミュノコア・リミテッド | 物質 |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| ES2528384T3 (es) | 2001-12-12 | 2015-02-09 | The Government Of The United States Of America, As Represented By The Secretary Department Of Healt | Métodos de utilización de inhibidores del receptor de adenosina para potenciar la respuesta inmunitaria y la inflamación |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| CA2476625A1 (en) | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20040047858A1 (en) | 2002-09-11 | 2004-03-11 | Blumberg Richard S. | Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof |
| US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US20090226474A1 (en) | 2004-05-27 | 2009-09-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20060034850A1 (en) | 2004-05-27 | 2006-02-16 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| JP5563194B2 (ja) | 2004-06-29 | 2014-07-30 | イムノコア リミテッド | 改変ｔ細胞レセプターを発現する細胞 |
| US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| EP2111231A4 (en) | 2007-02-13 | 2010-12-15 | Univ Northeastern | METHOD AND COMPOSITIONS FOR IMPROVING IMMUNE REACTIONS |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| US7615883B2 (en) | 2007-06-06 | 2009-11-10 | Meheen H Joe | Wind driven venturi turbine |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2212350B1 (en) | 2007-10-26 | 2013-08-28 | Governing Council of the University of Toronto | Treating chronic viral infection by targetting TIM-3 |
| EP3338895B1 (en) | 2007-12-07 | 2022-08-10 | Miltenyi Biotec B.V. & Co. KG | Sample processing systems and methods |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| PL2242773T3 (pl) | 2008-02-11 | 2017-11-30 | Cure Tech Ltd. | Przeciwciała monoklonalne do leczenia nowotworu |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| GB0906579D0 (en) | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
| EP2927240A1 (en) | 2008-08-25 | 2015-10-07 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| PL3006459T3 (pl) | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| US8883500B2 (en) | 2008-12-05 | 2014-11-11 | Northeastern University | Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US8741295B2 (en) | 2009-02-09 | 2014-06-03 | Universite De La Mediterranee | PD-1 antibodies and PD-L1 antibodies and uses thereof |
| LT2990421T (lt) | 2009-04-30 | 2018-04-25 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Anti-ceacam1 antikūnai ir jų panaudojimo būdai |
| US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
| ES2911246T3 (es) | 2009-11-03 | 2022-05-18 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
| JP6082997B2 (ja) | 2011-04-01 | 2017-02-22 | メモリアル スローン−ケタリング キャンサー センター | Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| JP6368243B2 (ja) | 2011-11-11 | 2018-08-08 | フレッド ハッチンソン キャンサー リサーチ センター | がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法 |
| EP2785375B1 (en) | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| EP2785743B1 (en) | 2011-12-01 | 2019-08-14 | The Brigham and Women's Hospital, Inc. | Anti-ceacam1 recombinant antibodies for cancer therapy |
| WO2013109759A1 (en) | 2012-01-17 | 2013-07-25 | Northeastern University | Methods and compositions for expanding immunosuppressive t regulatory cells in vitro and uses thereof |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| RU2665548C2 (ru) | 2012-05-03 | 2018-08-30 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ получения клеток, экспрессирующих т-клеточный рецептор |
| CA2916638C (en) | 2012-07-31 | 2021-01-12 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| PL2884999T3 (pl) | 2012-08-20 | 2021-07-05 | Fred Hutchinson Cancer Research Center | Sposób i kompozycje do immunoterapii komórkowej |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| CN104853776B (zh) | 2012-10-12 | 2021-04-09 | 布里格姆及妇女医院股份有限公司 | 免疫应答的增强 |
| US9405601B2 (en) | 2012-12-20 | 2016-08-02 | Mitsubishi Electric Corporation | In-vehicle apparatus and program |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| WO2014190273A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| EA201691144A1 (ru) | 2013-12-06 | 2016-11-30 | Селджин Корпорейшн | Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка |
| HRP20201906T1 (hr) | 2013-12-20 | 2021-04-02 | Fred Hutchinson Cancer Research Center | Označene kimerne efektorske molekule i njihovi receptori |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| ME03558B (me) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molekuli anti-lag-3 antiтela i njihove upotrebe |
| WO2015142675A2 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| EP4008725A1 (en) | 2014-05-02 | 2022-06-08 | The Trustees of the University of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
| CN106973568B (zh) * | 2014-10-08 | 2021-07-23 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| US9713375B1 (en) | 2015-02-26 | 2017-07-25 | Brett Einar Rahm | Collapsible portable table |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
-
2017
- 2017-12-01 MA MA046961A patent/MA46961A/fr unknown
- 2017-12-01 KR KR1020197019185A patent/KR20190104529A/ko not_active Ceased
- 2017-12-01 MX MX2019006285A patent/MX2019006285A/es unknown
- 2017-12-01 JP JP2019529636A patent/JP2019536460A/ja not_active Withdrawn
- 2017-12-01 US US16/465,520 patent/US20190358262A1/en not_active Abandoned
- 2017-12-01 BR BR112019011025A patent/BR112019011025A2/pt unknown
- 2017-12-01 AU AU2017368332A patent/AU2017368332A1/en not_active Abandoned
- 2017-12-01 CA CA3045508A patent/CA3045508A1/en not_active Abandoned
- 2017-12-01 CN CN201780085445.6A patent/CN110248678A/zh active Pending
- 2017-12-01 EP EP17825318.3A patent/EP3548083A1/en not_active Withdrawn
- 2017-12-01 KR KR1020237037956A patent/KR20230156808A/ko not_active Withdrawn
- 2017-12-01 WO PCT/US2017/064363 patent/WO2018102786A1/en not_active Ceased
-
2023
- 2023-03-23 JP JP2023046854A patent/JP2023078394A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536460A5 (enExample) | ||
| Wang et al. | Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response | |
| JP7656012B2 (ja) | 肺癌の処置のための抗ｐｄ－１抗体 | |
| Khalil et al. | The future of cancer treatment: immunomodulation, CARs and combination immunotherapy | |
| JP7054680B2 (ja) | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 | |
| Yonezawa et al. | Boosting cancer immunotherapy with anti-CD137 antibody therapy | |
| CN108025045B (zh) | 具有高亲和性和优良特异性的类tcr抗体结合域的亲和性实体及其用途 | |
| EP3157629B1 (en) | Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy | |
| US20190358262A1 (en) | Methods for modulation of car-t cells | |
| Freeman et al. | Immunotherapy in chronic lymphocytic leukaemia (CLL) | |
| WO2019114762A1 (zh) | 免疫效应细胞和辐射联用治疗肿瘤 | |
| Yang et al. | Combinations of radiotherapy with immunotherapy in cervical cancer | |
| Regzedmaa et al. | Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges | |
| De Felice et al. | Immune check-point in glioblastoma multiforme | |
| Cohen et al. | Therapeutic combinations of immune-modulating antibodies in melanoma and beyond | |
| US11564987B2 (en) | Combination immunotherapy for treatment of triple-negative breast cancer | |
| EP4588481A1 (en) | Composition for preventing or treating cancer, and method for preventing or treating cancer by using same, having abscopal effect | |
| Padda et al. | Tumor immunology | |
| RU2771759C2 (ru) | Антитела против pd-1 для лечения рака легких | |
| Marzolini et al. | Checkpoint blockade in cancer immunotherapy: squaring the circle | |
| WO2024204688A1 (ja) | 医薬 | |
| Myers et al. | Overcoming Cancer Tolerance with Immune Checkpoint Blockade | |
| Kato | Therapeutic Monoclonal Antibodies for Cancer: The Past, Present, and Future | |
| Chacko et al. | ROLE OF SINGLE IMMUNO-ONCOLOGY AGENTS AND COMBINATIONS IN CANCER THERAPY | |
| JP2023538568A (ja) | がん治療における使用のためのｌｆａ－１シグナル伝達メディエーター |